Press Releases :: Alzamend Neuro, Inc. (ALZN)

NASDAQ: ALZN

Nov 15, 2022 8:00am EST

Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline

Oct 31, 2022 8:00am EDT

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Oct 05, 2022 8:00am EDT

Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects

Sep 29, 2022 8:00am EDT

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Sep 22, 2022 8:00am EDT

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Jul 18, 2022 8:00am EDT

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Jun 03, 2022 8:00am EDT

Alzamend Neuro to Present at the 12th Annual LD Micro Invitational

May 17, 2022 8:00am EDT

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

May 05, 2022 8:00am EDT

Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Apr 28, 2022 6:30am EDT

Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

rss_feed News RSS